Tags

Type your tag names separated by a space and hit enter

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Mov Disord. 2009 Jul 15; 24(9):1339-43.MD

Abstract

Levodopa (L-dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis-related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long-term effect of chronic L-dopa/DDI treatment. Little is known about the acute effects of L-dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L-dopa and homocysteine after acute L-dopa/DDI administration in PD patients with different L-dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L-dopa absorption after standardized intake of 125 mg L-dopa/benserazide with determination of L-dopa, 3-O-methyl-dopa (3-OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3-OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L-dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L-dopa metabolism is an important component for homocysteine elevation after one time L-dopa/DDI administration in PD patients.

Authors+Show Affiliations

Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Germany. th.mueller@alexius.deNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

19425084

Citation

Müller, Thomas, and Wilfried Kuhn. "Homocysteine Levels After Acute Levodopa Intake in Patients With Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 24, no. 9, 2009, pp. 1339-43.
Müller T, Kuhn W. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord. 2009;24(9):1339-43.
Müller, T., & Kuhn, W. (2009). Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 24(9), 1339-43. https://doi.org/10.1002/mds.22607
Müller T, Kuhn W. Homocysteine Levels After Acute Levodopa Intake in Patients With Parkinson's Disease. Mov Disord. 2009 Jul 15;24(9):1339-43. PubMed PMID: 19425084.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. AU - Müller,Thomas, AU - Kuhn,Wilfried, PY - 2009/5/9/entrez PY - 2009/5/9/pubmed PY - 2009/10/22/medline SP - 1339 EP - 43 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 24 IS - 9 N2 - Levodopa (L-dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis-related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long-term effect of chronic L-dopa/DDI treatment. Little is known about the acute effects of L-dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L-dopa and homocysteine after acute L-dopa/DDI administration in PD patients with different L-dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L-dopa absorption after standardized intake of 125 mg L-dopa/benserazide with determination of L-dopa, 3-O-methyl-dopa (3-OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3-OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L-dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L-dopa metabolism is an important component for homocysteine elevation after one time L-dopa/DDI administration in PD patients. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/19425084/Homocysteine_levels_after_acute_levodopa_intake_in_patients_with_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.22607 DB - PRIME DP - Unbound Medicine ER -